| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Acadia Pharmaceuticals Inc. (ACAD) has 12 insiders with recent SEC Form 4 filings, including 0 buys and 10 sells. ACAD is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CFO | 66.1K | $1.90M | - | |
| 10% | 32.0K | $920.9K | - | |
| VP | 19.0K | $546.5K | -16,558 | |
| CEO | 14.8K | $425.9K | - | |
| Other | 13.1K | $376.5K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8, 2025 | Schneyer Mark C.59 | EVP, Chief Financial Officer | Sale+OE | 2,708 | $14.82 | $40,132.56 | -4.4% | +48.1% | +60.0% | |
| Apr 8, 2025 | Kihara James62 | Principal Accounting Officer | Sale+OE | 1,028 | $14.82 | $15,234.96 | -4.4% | +48.1% | +60.0% | |
| Mar 26, 2025 | Kihara James62 | Principal Accounting Officer | Sale+OE | 1,095 | $17.05 | $18,669.75 | -4.9% | +31.6% | +26.1% | |
| Mar 26, 2025 | Schneyer Mark C.59 | EVP, Chief Financial Officer | Sale+OE | 3,171 | $17.05 | $54,065.55 | -5.3% | +31.6% | +26.1% | |
| Mar 5, 2025 | Garofalo Elizabeth A.50 | Director | Sell | 4,919 | $18.23 | $89,673.37 | -21.8% | +21.6% | +23.9% | |
| Feb 24, 2025 | Schneyer Mark C.59 | EVP, Chief Financial Officer | Sale+OE | 773 | $19.96 | $15,429.08 | -1.4% | +13.9% | +26.3% | |
| Feb 24, 2025 | Kihara James62 | Principal Accounting Officer | Sale+OE | 475 | $19.96 | $9,481.00 | -2.3% | +13.9% | +26.3% | |
| Nov 19, 2024 | Kihara James62 | Principal Accounting Officer | Sale+OE | 4,073 | $16.81 | $68,467.13 | -17.0% | +21.8% | +42.5% | |
| Nov 19, 2024 | Schneyer Mark C.59 | EVP, Chief Financial Officer | Sale+OE | 10,259 | $16.81 | $172,453.79 | -16.1% | +21.8% | +42.5% | |
| Nov 19, 2024 | Teehan Brendan62 | EVP, COO, Head Of Commercial | Sale+OE | 10,329 | $16.81 | $173,630.49 | -14.3% | +21.8% | +42.5% |